Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01072916 · ClinicalTrials.gov registry record
Serine Proteases in Gastrointestinal Function and Irritable Bowel Syndrome (IBS)
A clinical trial, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- 60
- Enrollment target
NCT01072916 is a clinical trial that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 60 participants.
The verdict
NCT01072916 has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- 60 participants
- Enrollment target
Study Summary
The proposed pilot project for this seed grant focuses on the role of intestinal serine-proteases in the pathogenesis of diarrhea-predominant IBS (D-IBS). In this study we will further assess serine-protease activity in patients with D-IBS and also explore a possible mechanism by which these proteases can lead to alterations in intestinal physiology and symptoms in these patients. The general hypotheses for the proposed research are that (A) the levels of fecal serine-protease in patients with D-IBS are abnormally increased (B) this abnormal serine-protease activity leads to/is associated with an abnormal increase in intestinal permeability and therefore enables (C) chronic stimulation and activation of the mucosal immune system in these patients. In addition, it is aim to determine whither periodontal inflammation is associated with intestinal permeability and serine protease activity.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2009-02 |
| Est. Completion | 2015-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01072916
The ClinicalTrials.gov registry entry for NCT01072916 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01072916 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01072916 about?
NCT01072916 is a clinical study titled "Serine Proteases in Gastrointestinal Function and Irritable Bowel Syndrome (IBS)". The proposed pilot project for this seed grant focuses on the role of intestinal serine-proteases in the pathogenesis of diarrhea-predominant IBS (D-IBS). In this study we will further assess serine-protease activity in patients with D-IBS and also explore a possible mechanism by which these proteas...
What is the current status of trial NCT01072916?
This trial is currently completed. The enrollment target is 60 participants. The study started on 2009-02. Estimated completion is 2015-12.
Who is sponsoring clinical trial NCT01072916?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.